EP Advocacy Group Details 6 Key Policy Issues

Why It Matters

These policies directly affect EP physicians’ revenue, patient access to advanced rhythm therapies, and the pace of cardiovascular research, making advocacy crucial for the specialty’s sustainability.

Key Takeaways

• Medicare efficiency adjustment cuts EP physician payments 2.5%
• H.R. 879 aims to delay cut until 2030
• Carelon adds prior auth for AFib ablation CPT 93657
• LAAO reimbursement fell ~35% over two years
• Permanent telehealth policy needed for remote cardiac care

Pulse Analysis

Medicare’s 2026 Physician Fee Schedule introduced a controversial 2.5% efficiency adjustment, assuming AI‑driven gains will lower costs. EP specialists argue the reduction undervalues complex procedural work and could force practice closures, especially as inflation outpaces fee growth. The reintroduced Medicare Patient Access and Practice Stabilization Act (H.R. 879) seeks to suspend the cut until 2030 and demands empirical justification from CMS, signaling a broader push for data‑driven payment reforms that protect specialty services.

Beyond Medicare, private payers are tightening controls on high‑value EP interventions. Carelon’s new prior‑authorization requirement for CPT 93657 adds a peer‑to‑peer hurdle that may delay AFib ablations, while CMS’s 35% drop in left atrial appendage occlusion (LAAO) reimbursement threatens stroke‑prevention pathways. Simultaneously, regulatory and reimbursement obstacles continue to limit ambulatory surgery center (ASC) ablations, despite best‑practice guidelines that could expand capacity and lower costs. A permanent telehealth framework, still pending congressional action, would preserve remote monitoring and cardiac rehab services that have become integral to chronic rhythm management.

Research funding adds another layer of uncertainty. The NIH’s budgetary volatility, amplified by political interference, risks slowing innovation in device technology and novel therapies for arrhythmia patients. HRA’s monitoring of NIH advisory council meetings and the HELP Committee’s hearing on modernizing the institute underscores the specialty’s reliance on stable, science‑based funding to translate discoveries into clinical practice. Securing consistent research support is essential for maintaining the pipeline of next‑generation EP solutions and sustaining the field’s growth trajectory.